Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Influence Factors of the Efficacy of PD-1 Monoclonal Antibody Therapy in Advanced Pancreatic Cancer After Failure of First-line Chemotherapy by Using Multiomics Technology

NCT05201729 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05201729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05201729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Influence Factors of the Efficacy of PD-1 Monoclonal Antibody Therapy in Advanced Pancreatic Cancer After Failure of First-line Chemotherapy by Using Multiomics Technology
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Unknown status
Start date
August 1, 2021
Completion date
December 31, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma, pdac